Society for Clinical Research Sites Welcomes New Global Impact Partner
ELLICOTT CITY, Md., March 30, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year partnership with PRA Health Sciences (PRA), a leading CRO. PRA will participate as a Global Impact Partner (GIP), a relationship which exemplifies PRA’s commitment to promoting greater site sustainability for clinical research sites globally.
“PRA’s commitment to become a GIP is indicative of their eagerness to initiate and maintain positive site relationships; we are pleased they have selected SCRS as the catalyst,” commented Christine Pierre, SCRS President. “Collaboration with PRA is a significant strategic development for SCRS, and we are proud to welcome them as our newest GIP.”
“PRA is excited to join SCRS as a Global Impact Partner,” said Michael Brooks, PRA Senior Vice President and Head, Product Registration Americas. “PRA looks forward to maintaining a close engagement with the clinical research site community and, in partnership with SCRS, developing innovations and best practices to accelerate the development of new therapies for patients around the world.”
As a Global Impact Partner (GIP), PRA Health Sciences will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
